All In Biotech

Drug Trial Radar · NCT07923630

Validation & Intervention Testing for Aging, Longevity and Healthspan

Validation & Intervention Testing for Aging, Longevity and Healthspan (VITAL-H)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Dec 2030

Study completion Feb 2031

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Department of Health and Human Services
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study aims to address the gap between lifespan and healthspan (years of life free of age-related diseases and disabilities) by testing whether 2 approved U.S Food and Drug Administration (FDA) medications, dapagliflozin and semaglutide, can help people stay healthier as they age and delay the age-related functional decline. The study will test these medications over 36 months of treatment plus 6 months of observational follow up to see if they can safely maintain health and function during aging and eventually support their use for extending healthspan. This study is being done because there are limited ways to slow down the age-related health and functional decline, and few reliable ways to measure early changes in healthspan in humans. The 2 study drugs have shown promising results in laboratory and early human studies, but more evidence is needed.

Conditions

  • Aging
  • Functional Decline

Interventions

  • Dapagliflozin 10Mg Oral TabletDrug

    Participants will take one dapagliflozin plus one placebo pill daily for 36 months

  • Semaglutide oralDrug

    Participants will start taking a 1.5 mg semaglutide pill, titrated to 4 mg as tolerated, plus one placebo pill per day for 36 months.

  • PlaceboOther

    Participants will take two placebo pills daily for 36 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Continuous Short Physical Performance Battery SPPBTime frame: Baseline to end of study (approximately 36 months)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Texas Diabetes Institute

    San Antonio, Texas

  • San Antonio Food Bank

    San Antonio, Texas

  • Barshop Institute Mobile Research Clinic

    San Antonio, Texas

  • Sam and Ann Barshop Institute for Longevity & Aging Studies

    San Antonio, Texas

  • South Texas Veterans Health Care System

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.